NRIXNurix Therapeutics, Inc.Signing up patients
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
B-cell Lymphoma · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
9Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +9.2
3 insiders sold shares within a month
Since Oct 30, 2026 · was worth 10, fading over time
Worry score9
Score over time
- Stage
- Phase 3
- Patients
- 620 (planned)
- Started
- Aug 3, 2026
- Main results expected
- Oct 2029
- Fully finished
- Aug 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)
Measured over: Up to approximately 3.5 years
Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC
Measured over: Up to approximately 2.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 9.2, since 2026-10-30, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07516093 · record last updated 2026-08-31 · checked 2026-11-09 15:47 UTC